Humans have engaged in endurance running for millions of years 1, but the modern running
shoe was not invented until the 1970s. For most of human evolutionary history, runners …

Methods| Transplant recipients without prior polymerase chain reaction–confirmed COVID-19
were recruited from across the US to participate in this prospective cohort through a digital …

Background. Belatacept may impair humoral immunity, impacting the effectiveness of SARS-CoV-2
mRNA vaccines in transplant recipients. We investigated immunogenicity after SARS-…

Background: Patients with rheumatic and musculoskeletal diseases (RMDs) are at increased
risk for SARS-CoV-2 infection because of both the immunomodulatory effects of their …

Methods| Transplant recipients across the US were recruited though social media to participate
in this prospective cohort, and those who underwent SARS-CoV-2 vaccination between …

Background: The antibody response after 2 doses of an mRNA vaccine against SARS-CoV-2
is excellent in the general population (1), but the response is different in recipients of solid …

COVID‐19 is a novel, rapidly changing pandemic: consequently, evidence‐based
recommendations in solid organ transplantation (SOT) remain challenging and unclear. To …

All authors participated in conception or design of the work or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising it critically for important …

The immune response to SARS-CoV-2 messenger RNA (mRNA) vaccines in patients with
rheumatic and musculoskeletal diseases (RMD) is undefined because these individuals were …

Objective To evaluate disease flare and postvaccination reactions (reactogenicity) in
patients with rheumatic and musculoskeletal diseases (RMDs) following 2‐dose SARS–CoV‐2 …